You are here

Home » Reports

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 62 results
 
  • Record 1 TO 62

  1. THE PRIMARY OBJECTIVE OF THE PROPOSED PROGRAM IS THE ULTIMATE DEVELOPMENT OF A PRACTICAL WEARABLE AIR POWER SUPPLY FOR AN IMPLANTED PNEUMATIC ARTIFICIAL HEART.

    SBC: Amnis Corporation            Topic: N/A

    THE PRIMARY OBJECTIVE OF THE PROPOSED PROGRAM IS THE ULTIMATE DEVELOPMENT OF A PRACTICAL WEARABLE AIR POWER SUPPLY FOR AN IMPLANTED PNEUMATIC ARTIFICIAL HEART. THE PROPOSAL ADDRESSES ITSELF TO THE CONCEPT OF A WEARABLE POWER SUPPLY FOR A PNEUMATIC HEART THAT HAS BEEN IMPLANTED IN AN AMBULATORY PATIENT, AND SEEKS TO IDENTIFY THE SMALLEST AND LIGHTEST PNEUMATIC DRIVE FOR THE APPLICATION, SO THAT A U ...

    SBIR Phase I 1984 Department of Health and Human Services

  2. WEARABLE, NON-GRAVITY-DEPENDENT INFUSION DEVICE

    SBC: Amnis Corporation            Topic: N/A

    N/A

    SBIR Phase I 1984 Department of Health and Human Services

  3. WEARABLE RESPIRATOR

    SBC: Amnis Corporation            Topic: N/A

    N/A

    SBIR Phase I 1984 Department of Health and Human Services

  4. Vascular Targeting for Imaging and Treatment of Benign Prostatic Hyperplasia

    SBC: ANDROBIOSYS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Benign Prostatic Hyperplasia/Hypertrophy is a major health problem in the United States, with one-in-three men having urologic problems. Currently available treatment modalities include alpha-blockers that do not affect the underlying pathologic process, and 5-alpha-reductase inhibitors that have significant systemic side-effects. We have discovered that human ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health

  5. Primary Xenografts of Human Tissue as Surrogates of Cancer In Situ

    SBC: ANDROBIOSYS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): AndroBioSys, Inc. is dedicated to the development of human tissue-based in vivo tools capable of selecting better targeted agents for clinical trials by improved preclinical testing. AndroBioSys has developed the technology for reproducible implantation of primary xenografts of benign and malignant human prostate and kidney tissue. Xenografts have been establis ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health

  6. Novel therapeutic for Alcoholic Liver Disease

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Alcoholic Liver Disease (ALD) is a progressive liver disease that in advanced stages can result in cirrhosis and liver failure. ALD can be divided in various stages of development: (1) mild alcoholic liver injury, (2) steatosis, (3) alcoholic hepatitis, (4) alcoholic liver fibrosis and (5) cirrhosis. Liver fibrosis is a form of scar formation that is found in a ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health

  7. Phase I Study of BB3 in Dialysis Patients

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Kidney transplantation is the most effective therapeutic modality for end-stage renal disease; it offers a better quality of life and a longer survival. Despite improvements in surgical and organ preservation techniques over the last decade, renal dysfunction and/or failure remains a significant problem following transplantation. Ischemia-reperfusion injury ass ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health

  8. Novel Therapeutic for Duchenne Muscular Dystrophy (DMD)

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): A significant body of literature indicates that Hepatocyte Growth Factor (HGF) via potent and direct anti-fibrotic activity protects many organs from the fibrosis-driven pathology. In addition, HGF has been shown to also promote muscle progenitor cells to proliferate to promote the regenerative capacity of the muscle in response to injury or significant work ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health

  9. In Vitro Feasibility of a Rapid Response Continuous Glucose Sensor

    SBC: Ultradian Diagnostics, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Numerous research publications have demonstrated the benefits of continuous glucose monitoring for better glucose control and reduced glycated hemoglobin (HbA1c) levels; however, to improve efficacy, significant improvements in the performance of implanted glucose sensors are required. The proposed Phase 1 research is focused on developing a rapid, microsecond, ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health

  10. A NETWORKED COMPUTER-MEDIATED SMOKING CESSATION PROGRAM

    SBC: Behavioral Health Systems Inc            Topic: N/A

    N/A

    SBIR Phase I 1984 Department of Health and Human Services
US Flag An Official Website of the United States Government